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Purpose: To describe the onset of ﬂoaters and reduction in contrast sensitivity (CS) following successful
pharmacologic vitreolysis with ocriplasmin for the treatment of vitreo-macular traction (VMT) in a pa-
tient with previously normal CS.
Observations: A 65-year-old woman with a past ocular history of normal visual acuity (VA ¼ 20/26) and
contrast sensitivity (1.81% Weber) presents with a 4-month history of distortions. VA decreased to 20/40
and Optical Coherence Tomography (OCT) demonstrated VMT. Pharmacologic vitreolysis was performed
with intravitreal ocriplasmin. Ten weeks later the patient complained of ﬂoaters and was found to have a
PVD and complete resolution of VMT. VA was still 20/40, but contrast sensitivity decreased by more than
100% to 3.77%Weber. After 6 months of attempted coping, this did not improve, so limited vitrectomy
was performed. Post-operative VA ¼ 20/26 and CS improved by 46% from 3.77%W to 2.03%W (normal).
Conclusion: and importance: This case highlights a little discussed consequence of PVD induction by
successful pharmacologic vitreolysis e the development of clinically signiﬁcant ﬂoaters. The resulting
reduction of contrast sensitivity was normalized by limited vitrectomy, strongly suggesting that the
detached vitreous was the cause.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Anomalous posterior vitreous detachment (PVD) causes a range
of macular disorders, including vitreo-macular traction (VMT).1 For
decades, vitrectomy has been the only therapeutic modality.
Recently, however, pharmacologic vitreolysis has become available
as a non-surgical approach to treat VMT and macular holes.2,3 The
ﬁrst approved drug for pharmacologic vitreolysis is ocriplasmin, a
truncated form of the human serine protease plasmin. This non-
speciﬁc protease has both liquefactant activity to liquefy gel vitre-
ous3,4 and interfactant properties that weaken vitreo-retinal
adhesion, both necessary to induce PVD.2e4 Results of preclinical5
and clinical6 studies have shown that intravitreal ocriplasmin in-
jection can induce PVD and relieve VMT. Some patients, however,
experience disturbed vision following injection, and the etiology is
not always clear.7e9 The objective of this case report is to analyze aMacula Retina, 7677 Center
.
g).
Inc. This is an open access article upotential untoward effect of pharmacologic vitreolysis for VMT e
the development of subjectively bothersome ﬂoaters with objective
reduction of contrast sensitivity.
The following presents a case of clinically signiﬁcant ﬂoaters
that developed following pharmacologic vitreolysis for VMT with
ocriplasmin. The etiology is identiﬁed as PVD and the impact on
vision is assessed objectively using contrast sensitivity testing that
yields quantiﬁcation known as the Weber index10,11:
%W ¼ [LuminancemaxLuminancemin]/Luminancemax2. Case report
The patient providedwritten consent for publication of personal
information including medical record details and photographs.
On initial presentation, a 65-year-old woman with hypothy-
roidism, hypertrophic cardiomyopathy, hypertension, and hyper-
cholesterolemia was diagnosed with asymptomatic vitreo-macular
adhesion (Fig. 1A). The patient did not complain of subjectivender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Best corrected (4.75e0.75  38) ETDRS visual acuity (BCVA)
measured 20/26-2.
One year later the patient presented with the chief complaint of
decreased vision with distortions. BCVA was 20/40 and SD-OCT
(Optos, Mass) showed anomalous PVD with signiﬁcant vitreo-
foveal traction, a central macular cyst, and macular thickening to
345mm (Fig. 1B). Pharmacologic vitreolysis was performed withFig. 1. A: SD-Optical Coherence Tomography image shows vitreo-macular adhesion with
macular traction with macular cysts and foveal thickening to 345 mm. C: SD-OCT imaging
with ocriplasmin. A reduction in macular cysts can be seen as well as reduced macular swe
pharmacologic vitreolysis with ocriplasmin shows disappearance of macular cysts and signiﬁ
on the detached posterior vitreous cortex in front of the fovea.intravitreal ocriplasmin. One week after injection, BCVA remained
20/40 and OCT showed persistent vitreo-foveal traction with
macular cysts. Ten weeks later, the patient noted the sudden onset
of ﬂoaters. SD-OCT imaging showed vitreo-foveal separation
(Fig. 1B) with release of traction and a 95 mm decrease in macular
thickening (345mm to 250 mm) (Fig. 1B,C). The patient was advised
to try coping with the ﬂoaters.foveal thickening of 280 mm. B: SD-OCT imaging shows anomalous PVD with vitreo-
shows the release of vitreo-macular traction 10 weeks after pharmacologic vitreolysis
lling from 345 mm to 250 mm in the foveal region. D: SD-OCT imaging 4 months after
cant reduction in thickening to 175 mm. However, there was PVD with a dense opacity
Table 1
Chronology of changes in contrast sensitivity from normal baseline to abnormal levels following pharmacologic vitreolysis, then back to normal after limited
vitrectomy.
Normal baseline Post-pharmacologic vitreolysis induced PVD Post-vitrectomy
1.81% W 3.77% W (9 months post-injection) 2.03% W (3 months post-vitrectomy)
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some ﬂoaters persisted and contrast sensitivity (CS) was dimin-
ished from 1.81%Weber (prior to PVD) to 3.77%Weber, which is
within the range of abnormal CS levels that were previously shown
to respond to surgical intervention.11,12 SD-OCT imaging revealed
resolution of VMT, but there was PVD with a dense vitreous opacity
in the detached posterior vitreous cortex (Fig. 1D).
Given the chronicity of the ﬂoaters, the patient's considerable
subjective dissatisfaction with vision, and the objective ﬁnding of
diminished contrast sensitivity, limited vitrectomy was perform-
ed.11e13 2 weeks after surgery contrast sensitivity improved by 46%
from 3.77%W pre-op to 2.03%W post-op. Acutely, CS remained
normal at 1 month, and 3 months. Long-term follow-up showed
that 1.5 years after vitrectomy CS was still normal at 2.43%Weber.
3. Discussion
More than four decades ago, Parel, Machemer, and Buettner
invented vitrectomy surgery,14 which has since been the mainstay
of therapy for VMT and other vitreo-retinal disorders. However
surgery is now being replaced in some circumstances by pharma-
cologic vitreolysis,2e6 as approved by the US FDA and European
EMA with ocriplasmin to treat patients with symptomatic vitreo-
macular adhesion and VMT, with or without macular hole. Some
post-marketing reports8,9 have linked ocriplasmin to acute, tran-
sient visual dysfunction, which in most (but not all) cases resolve.
Floaters were experienced by as many as 17% of patients in pre-
approval clinical trials.6 In the MIVI-TURST trials, 13.4% of patients
treated with Ocriplasmin had a total PVD, while only 3.7% of the
placebo group presented with PVD by the primary end point. In
addition, of those that were treated with Ocriplasmin (n ¼ 465),
16.8% reported developing vitreous ﬂoaters, while only 7.5% of the
placebo group (n ¼ 187) reported having ﬂoaters.7 The number of
those that were successfully treated patients who developed
ﬂoaters was not speciﬁed, compared to those that were not
successful.
The case reported herein developed PVD following successful
pharmacologic vitreolysis, but there were subjectively bothersome
ﬂoaters. Although there was therapeutic resolution of VMT, the
ﬂoaters were associated with diminution of previously docu-
mented normal contrast sensitivity. (See Table 1).
Past studies have identiﬁed PVD as the cause of clinically sig-
niﬁcant ﬂoaters in two-thirds of cases, with diminution in CS on the
order of 67%, on average.11 Fortunately, this and other studies12,13
found that CS can be restored back to normal with vitrectomy, as
was the case with the patient reported herein. But the effects of
vitrectomy are not the point of this case report. This aspect is
presented solely to demonstrate that the restoration of CS to
normal levels following vitrectomy strongly implicates vitreous asthe cause of decreased CS following successful pharmacologic vit-
reolysis, in this case with ocriplasmin.
4. Conclusions
The case reported herein provides evidence that the induction of
PVD by pharmacologic vitreolysis with ocriplasmin can induce
clinically signiﬁcant ﬂoaters and reduce previously normal contrast
sensitivity. Removal of the vitreous resulted in resolution of the
ﬂoater symptoms and restored contrast sensitivity to normal.
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